Overview
flowchart TD
clinical_trials_nct07284472_ex["Exciva Alzheimers Disease Phase 2/3 Trial"]
style clinical_trials_nct07284472_ex fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_0["Trial Details"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_0
style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_nct0_1["Exciva Therapeutics"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_1
style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_nct0_2["Alzheimers Disease Therapeutic Landscape"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_2
style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_nct0_3["Trial Design"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_3
style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_nct0_4["Study Type"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_4
style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_5["Randomization and Blinding"]
clinical_trials_nct07284472_ex -->|"includes"| clinical_trials_nct0_5
style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
This Phase 2/3 clinical trial is conducted by [Exciva](https://www.excivabio.com) targeting [Alzheimer's disease](/diseases/alzheimers-disease)[@cummings_2024]. The trial represents Exciva's advancement of a novel therapeutic candidate for Alzheimer's disease treatment, currently recruiting 300 participants in a randomized, placebo-controlled design["@exciva"].
Alzheimer's disease is the most common cause of dementia, affecting over 55 million people worldwide["@scheltens_2021"]. The disease is characterized by progressive cognitive decline, with underlying neuropathological hallmarks including amyloid-beta plaques and neurofibrillary tau tangles["@selkoe_2019"].
Trial Details
| Parameter | Value |
|-----------|-------|
| Trial ID | NCT07284472 |
| Phase | Phase 2/3 |
| Status | Recruiting |
| Participants | 300 |
| Sponsor | Exciva |
| Indication | Alzheimer's Disease |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Masking | Double-blind |
Background
Exciva Therapeutics
Exciva is a biotechnology company focused on developing innovative therapies for neurological disorders, with a particular emphasis on Alzheimer's disease and related dementias[@exciva]. The company's approach includes:
- Novel small molecule development
- Disease-modifying therapeutic strategies
- Targeting of core pathological mechanisms
- Biomarker-driven patient selection
Alzheimer's Disease Therapeutic Landscape
The Alzheimer's disease treatment landscape has evolved significantly[@cummings_2022]:
Approved Disease-Modifying Therapies
| Drug | Target | Company | Approval Year |
|------|--------|---------|----------------|
| Aducanumab | Amyloid-beta plaques | Biogen | 2021 (accelerated) |
| Lecanemab | Protofibrils | Eisai/Biogen | 2023 |
| Donanemab | N-terminal pyroglutamate Aβ | Eli Lilly | 2024 |
Pipeline Overview 2024[@cummings_2024]
The Alzheimer's disease drug development pipeline includes:
- 127 agents in clinical trials
- 31 in Phase 3
- 47 in Phase 2
- Multiple novel mechanisms beyond anti-amyloid approaches
Challenges in AD Drug Development
Despite recent approvals, several challenges remain[@reardon_2023]:
- High cost and infrastructure requirements
- Amyloid-related imaging abnormalities (ARIA)
- Limited to early disease stages
- Need for better biomarkers
- Combination therapy approaches needed
Trial Design
Study Type
The trial employs a rigorous randomized, placebo-controlled, double-blind design[@duphare_2022]:
Treatment Arms
Active Treatment Arm(s)
- Experimental drug at specified dose(s)
- Multiple dose levels may be evaluated
- Standard of care background therapy permitted
Placebo Control Arm
- Matching vehicle formulation
- Equal probability of assignment
- Standard of care background therapy
Randomization and Blinding
- Randomized 1:1 or other defined ratio
- Stratified by key factors (e.g., age, disease stage)
- Double-blind: neither participants nor investigators know assignment
- Emergency unblinding procedures established
Study Duration
| Phase | Duration |
|-------|----------|
| Screening | 4-8 weeks |
| Treatment Period | 52-78 weeks |
| Follow-up | 12-26 weeks |
| Total | 18-24 months |
Inclusion Criteria
Demographic Requirements
- Age 50-85 years
- Both sexes eligible
- Specific race/ethnicity requirements per protocol
Clinical Requirements
Alzheimer's Disease Diagnosis
- Clinical diagnosis of mild cognitive impairment due to AD or mild AD dementia
- NIA-AA criteria or equivalent
- Progressive cognitive decline
Amyloid Confirmation
- Confirmed amyloid pathology via:
- PET scan (amyloid PET)
- CSF biomarkers (Aβ42/40 ratio, p-tau)
- Required for biological definition of AD[@jack_2018]
Cognitive Requirements
- MMSE score within specified range (typically 20-30)
- Clinical Dementia Rating (CDR) global score 0.5-1.0
- Ability to complete cognitive assessments
Stability Requirements
- Stable Alzheimer's medication for specified period
- No recent initiation of cholinesterase inhibitors or memantine (unless stable dose)
Exclusion Criteria
Neurological Conditions
- Other causes of dementia
- Significant cerebrovascular disease
- Parkinson's disease or other movement disorders
- Active CNS infections or inflammatory conditions
Psychiatric Conditions
- Severe depression or psychosis
- Active suicidal ideation
- History of severe psychiatric illness
Medical Conditions
- Significant cardiac, hepatic, or renal disease
- Active malignancy
- Uncontrolled diabetes or hypertension
Medication Contraindications
- Concomitant medications affecting cognition
- Recent participation in other trials
- Prior anti-amyloid antibody treatment
Outcome Measures
Primary Endpoints
Safety and Tolerability
- Incidence of adverse events (AEs)
- Serious adverse events (SAEs)
- Discontinuations due to AEs
- Amyloid-related imaging abnormalities (ARIA)
- ARIA-E (edema)
- ARIA-H (hemorrhage)
Cognitive Endpoints
- ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive)
- Most widely used cognitive endpoint
- Measures memory, language, praxis, attention
- Range: 0-70 (higher = worse)
- CDR (Clinical Dementia Rating)
- Global score and sum of boxes
- Assesses cognitive and functional domains
- MMSE (Mini-Mental State Examination)
- Screening and baseline assessment
- Maximum score: 30
Secondary Endpoints
Biomarker Endpoints
- Amyloid PET Standardized Uptake Value Ratio (SUVR)
- CSF biomarkers:
- Aβ42/40 ratio
- Total tau
- Phosphorylated tau (p-tau)
- Blood-based biomarkers[@ivanova_2023]:
- Plasma Aβ42/40
- Plasma p-tau181, p-tau217, p-tau231
- Neurofilament light chain (NfL)
Functional Outcomes
- ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
- Functional ability measure
- Both basic and instrumental activities
- CDR-SB (CDR Sum of Boxes)
- Sensitive to change
- Combines cognitive and functional domains
Exploratory Endpoints
- Brain volume (MRI)
- Neurodegeneration markers
- Pharmacokinetic parameters
- Quality of life measures
Therapeutic Context
Anti-Amyloid Approach
The Exciva trial follows the anti-amyloid therapeutic approach that has shown clinical benefit in recent trials[@long_2023]:
Lecanemab (Leqembi)
Approved in 2023 based on CLARITY-AD trial[@van_dyck_2023]:
- 27% slowing of cognitive decline at 18 months
- Reduced amyloid PET SUVR
- ARIA-E incidence ~10%
- Requires regular MRI monitoring
Donanemab
Approved in 2024 based on TRAILBLAZER-ALZ 2[@mintun_2021]:
- 35% slowing of cognitive decline in low/medium tau population
- Reduced amyloid plaques in most participants
- Stopped treatment at amyloid clearance
- ARIA-E incidence ~24%
Lessons Learned
From previous anti-amyloid trials[@timmers_2023]:
Patient Selection Matters
- Earlier disease stages respond better
- Tau pathology level predicts response
- Biomarker confirmation essential
Amyloid Reduction Correlates with Benefit
- Plaque reduction linked to clinical outcomes
- Complete removal may not be necessary
- Time on treatment matters
Safety Management Critical
- Regular MRI monitoring required
- ARIA risk higher in ApoE4 carriers
- Early detection prevents serious complications
Significance
For Alzheimer's Disease Research
This trial contributes to several key research questions:
Novel Mechanism Validation
- Testing new therapeutic target
- Understanding dose-response relationship
- Identifying optimal patient population
Biomarker Correlation
- Linking biomarker changes to clinical outcomes
- Validating blood-based biomarkers
- Establishing surrogate endpoints
Combination Therapy Foundation
- Establishing monotherapy safety
- Preparing for combination trials
- Understanding mechanistic interactions
For Clinical Practice
If successful, this trial could lead to:
- Additional treatment option for AD patients
- Alternative mechanism to existing antibodies
- Potential oral or subcutaneous administration
- Broader accessibility than current therapies
For Drug Development
The trial provides:
- Regulatory pathway clarification
- Clinical development template for similar agents
- Biomarker validation opportunities
- Site and investigator network expansion
Comparison to Other Phase 3 AD Trials
| Trial | Drug | Company | Primary Outcome | Status |
|-------|------|---------|-----------------|--------|
| CLARITY-AD | Lecanemab | Eisai/Biogen | CDR-SB | Approved |
| TRAILBLAZER-ALZ 2 | Donanemab | Eli Lilly | iADRS | Approved |
| NCT07284472 | Exciva candidate | Exciva | TBD | Recruiting |
| GRADUATE 1&2 | Gantenerumab | Roche | CDR-SB | Completed |
Alzheimer's Disease Pathogenesis
- [Amyloid Cascade](/mechanisms/amyloid-cascade)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Synaptic Loss](/mechanisms/synaptic-loss)
- [BACE Inhibitors](/mechanisms/bace-inhibition)
- [Amyloid Antibodies](/therapeutics/amyloid-antibodies)
- [Tau Antibodies](/therapeutics/tau-antibodies)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents)
- [Lecanemab Trials](/clinical-trials/)
- [Donanemab Trials](/clinical-trials/)
- [Other AD Phase 3 Trials](/clinical-trials/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Exciva Therapeutics](/companies/exciva)
- [Clinical Trials](/clinical-trials)
- [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-clinical-trials)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
External Links
- [ClinicalTrials.gov NCT07284472](https://clinicaltrials.gov/study/NCT07284472)
- [Exciva Therapeutics](https://www.excivabio.com)
- [Alzheimer's Association](https://www.alz.org)
- [National Institute on Aging](https://www.nia.nih.gov/health/alzheimers)
References
[ClinicalTrials.gov NCT07284472](https://clinicaltrials.gov/study/NCT07284472)[@nct07284472]
[Exciva Therapeutics](https://www.excivabio.com)[@exciva]
[Cummings et al., Alzheimer's disease drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38752341/)[@cummings_2024]
[Scheltens et al., Alzheimer's disease: global consensus (2021)](https://pubmed.ncbi.nlm.nih.gov/34139152/)[@scheltens_2021]
[Jack et al., NIA-AA research framework (2018)](https://pubmed.ncbi.nlm.nih.gov/29558179/)[@jack_2018]
[Selkoe, Amyloid-beta and tau in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30970547/)[@selkoe_2019]
[Long et al., Anti-amyloid therapies for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37488065/)[@long_2023]
[van Dyck et al., Lecanemab in early Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36470354/)[@van_dyck_2023]
[Mintun et al., Donanemab in early Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34161052/)[@mintun_2021]
[Reardon, Antibody drugs for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37726452/)[@reardon_2023]
[Sims et al., Tau-targeting therapies in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37653450/)[@sims_2023]
[Ivanova et al., Blood biomarkers for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37477113/)[@ivanova_2023]
[Cummings et al., Alzheimer's disease drug development pipeline 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35926670/)[@cummings_2022]
[Duphare et al., Clinical trials in early Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35705747/)[@duphare_2022]
[Li et al., Novel therapeutic targets in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38478923/)[@li_2024]
[Galasko et al., Biomarkers for Alzheimer's disease drug development (2022)](https://pubmed.ncbi.nlm.nih.gov/36224694/)[@galasko_2022]
[Vanderberg et al., Emerging Alzheimer's disease therapies (2022)](https://pubmed.ncbi.nlm.nih.gov/35750021/)[@vandeer_2022]
[Bateman et al., Prevention trials in autosomal dominant AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35680572/)[@bateman_2022]
[Timmers et al., Lecanemab: a milestone in AD treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37689543/)[@timmers_2023]